Member Info for Brysoa

“Personality” counts for very little in this kind of forum. The data speaks for itself and the presentation will be 100% per the agreed company script.

So Janssen is “funding” UNIVERSAL, AZ are providing the funding for a key component of the study (specimen testing) and Synairgen are providing access to equipment and research nurses’ time. Interesting collaborative effort. May one assume that all 3 companies have access to the results of the study?

Aether, is this interesting statement a guess or evidence-based?

There has been an interesting flurry of buy activity over the past 24 hours or so with a corresponding upward blip in sp. I wonder why?

Super spotting by TP in the first place - a forensic mind!

Yup, Fruits, it does look as if it’s been planned well in advance. I like that!

Yes, it is an advert. Synairgen must believe that money spent on this kind of high end promotion is worthwhile. This, together with their staff recruitment and retention performance of late suggests strongly to me that there is something positive afoot down Southampton way.

Ok, it’s not the Holy Grail we have all been waiting for, and of course it was a paid-for event but it’s still good to see promotion of awareness of Synairgen in a very prestigious publication. Of course this pr initiative is a side show to the main event but a necessary one, imo, and one that is being carried out quite well by the company

Based on the facts at our disposal - a company retaining and recruiting key positions and building its profile through social media engagement, presenting at important scientific and medical meetings, holding funding for at least another year BUT maintaining radio-silence on the commercial announcement front, i am fairly certain that something very positive is afoot that is either not quite at the stage of being ready to be announced or, more likely imo, is the subject of an NDA. I retain confidence in team SNG and don’t expect my paws to be buttered with RNSs when there is nothing that can be publicly said. As shareholders we have a right to material information about the company’s progress as and when it is material, not to meaningless tit-bits just because it’s the second Tuesday in the month.

EGM - forget it. Stupid idea!

… to play for.

Re-reading Dr Monk’s paper, “The Need - and Opportunity - to develop Broad-Spectrum Antivirals”, I am reminded of how different the respiratory viral infection landscape was a mere 36 months ago and how central to the changes Synairgen has been. Suddenly we live in an era where discussion of the possibility and the importance of rapid viral testing, the importance of innate immunity, the strategy of host-directed - and therefore virus/variant agnostic - therapeutics is commonplace. We recognise, as never before, the burden of viral respiratory illness at an individual and population level as well as the way it tests the resilience of health services.

We have seen the strengths and weaknesses of mono-therapies, notably mono-clonal antibodies, and of vaccination strategies and the early willingness of decision makers to jump on the bandwagon of these interventions to the exclusion of support for other emerging therapeutic strategies. We are now seeing an emerging awareness that this stool needs a 3rd leg to constitute an effective overall interventional strategy. And we are seeing an awareness that part of that strategy must be preparedness for future new and different viral pandemics, necessitating governmental motivation and relevant investment, including stockpiling of appropriate therapeutics.

The Covid pandemic has moved Synairgen and its agenda centre stage in a way scarcely imaginable in December 2019. The pandemic has provided an environment in which Synairgen and its investigation of SNG001 have transitioned in a remarkably short period of time from the work a virtually unknown academically-led venture outside the infamous “golden-triangle” of Oxford, Cambridge and London to a company contributing and, to some extent leading, this international endeavour. This has not been without cost and some mistakes and mis-steps have occurred along the way. That is the nature of bio-medical research and drug discovery. The challenges of getting SNG001 over the conclusive demonstration of efficacy line and the commercialisation line have yet to be met.

Synairgen has risen to the challenge remarkably for an enterprise of its size and nature over these short 36 months. They have more to do. To all appearances their efforts and the results to date of their investigative programme are taken seriously in governmental, regulatory and industry circles. Key opinion leaders like Rick Bright are not shy about expressing support for the interferon thesis in general and SNG001 in particular

As the Covid pandemic transitions into just another endemic respiratory viral problem like influenza, RSV, etc, and as public weariness with booster vaccination, fuelled by rational or irrational fears regarding vaccine safety in the long term, becomes ever more pronounced, the environment will continue to morph in favour of the need for host-directed micro-organism agnostic therapeutics. With prudent management and support there is everything to play f

Every good promotional message merits repetition. Foundation of good advertising.

The jargon in the ad is very current, “ potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Synairgen is led by a team of industry experts and world-renowned academics, dedicated to creating pandemic-ready respiratory treatments we can all believe in”

Couldn’t agree with you less, Tattyhead.

A lot of posters here should not be invested in drug-discovery companies. Oh, wait a minute, they’re not! They are just wasting the time of the rest of us!

Thank you, Alpha-dog. I missed that reference in the RNS. Pretty fundamental finding insofar as hospitalisation was/is a proxy for clinical deterioration.

I see from one of the two presentation posted on the SNG website today that, in the ACTIV-2 phase 2 study, 1% of patients in the SNG001 group were hospitalised compared to 7% in the placebo group. I’m not aware that this has been reported previously. Small numbers and not statistically significant but still ….

Passing through Southampton - bought a jumper at M&S. No sign of RM, though. Is this a sign?

iDWeek is not a trade fair. The key to a successful presentation is in the data.